ERBB2 and breast cancer: Table 1 shows the clinico-pathological parameters of the study cohort by the HER2 score, including 120 (77.9%) BC patients who had HER2 IHC 3+, and 34 (22.1%) had HER2 IHC 2+/SISH+.